IceCure Medical (ICCM) Cash & Equivalents (2020 - 2026)

IceCure Medical (ICCM) has 7 years of Cash & Equivalents data on file, last reported at $8.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 34.35% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (up 34.35% YoY) and the FY2025 annual result came in at $8.9 million, up 17.62% from the prior year.
• Cash & Equivalents declined to $8.1 million in Q1 2026 per ICCM's latest filing, from $8.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $23.7 million in Q4 2022 and bottomed at $6.0 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $8.5 million (2025), against an average of $10.8 million.
• The widest annual swing landed in 2023, when Cash & Equivalents sank 55.48%; it then surged 34.35% in 2026.
• Tracing ICCM's Cash & Equivalents over 5 years: stood at $23.7 million in 2022, then sank by 55.48% to $10.5 million in 2023, then decreased by 28.19% to $7.6 million in 2024, then grew by 17.62% to $8.9 million in 2025, then declined by 8.79% to $8.1 million in 2026.
• Per Business Quant, the three latest ICCM Cash & Equivalents figures stand at $8.1 million (Q1 2026), $8.9 million (Q4 2025), and $6.0 million (Q1 2025).

Peer Comparison